Regulation and dysregulation of Epstein-Barr virus latency: Implications for the development of autoimmune diseases

被引:145
|
作者
Niller, Hans Helmut [2 ]
Wolf, Hans [2 ]
Minarovits, Janos [1 ]
机构
[1] Natl Ctr Epidemiol, Microbiol Res Grp, H-1529 Budapest, Hungary
[2] Univ Regensburg, Dept Microbiol & Hyg, D-93053 Regensburg, Germany
关键词
Epstein-Barr virus; latency control; epigenetic regulation; autoimmune diseases; B-cell tolerance checkpoints; immune surveillance defects;
D O I
10.1080/08916930802024772
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epstein-Barr virus (EBV) is a human herpesvirus hiding in a latent form in memory B cells in the majority of the world population. Although, primary EBV infection is asymptomatic or causes a self-limiting disease, infectious mononucleosis, the virus is associated with a wide variety of neoplasms developing in immunosuppressed or immunodeficient individuals, but also in patients with an apparently intact immune system. In memory B cells, tumor cells, and lymphoblastoid cell lines (LCLs, transformed by EBV in vitro) the expression of the viral genes is highly restricted. There is no virus production (lytic viral replication associated with the expression of all viral genes) in tight latency. The expression of latent viral oncogenes and RNAs is under a strict epigenetic control via DNA methylation and histone modifications that results either in a complete silencing of the EBV genome in memory B cells, or in a cell-type dependent usage of latent promoters in tumor cells, germinal center B cells, and LCLs. Both the latent and lytic EBV proteins are potent immunogens and elicit vigorous B- and T-cell responses. In immunosuppressed and immunodeficient patients, or in individuals with a functional defect of EBV-specific T cells, lytic EBV replication is regularly activated and an increased viral load can be detected in the blood. Enhanced lytic replication results in new infection events and EBV-associated transformation events, and seems to be a risk factor both for malignant transformation and the development of autoimmune diseases. One may speculate that an increased load or altered presentation of a limited set of lytic or latent EBV proteins that cross-react with cellular antigens triggers and perpetuates the pathogenic processes that result in multiple sclerosis, systemic lupus erythematosus (SLE), and rheumatoid arthritis. In addition, in SLE patients EBV may cause defects of B-cell tolerance checkpoints because latent membrane protein 1, an EBV-encoded viral oncoprotein can induce BAFF, a B-cell activating factor that rescues self-reactive B cells and induces a lupus-like autoimmune disease in transgenic mice.
引用
收藏
页码:298 / 328
页数:31
相关论文
共 50 条
  • [31] Epstein-Barr virus and cytomegalovirus in autoimmune diseases - Are they truly notorious? A preliminary report
    Barzilai, O.
    Sherer, Y.
    Ram, M.
    Izhaky, D.
    Anaya, J. M.
    Shoenfeld, Y.
    AUTOIMMUNITY, PT D: AUTOIMMUNE DISEASE, ANNUS MIRABILIS, 2007, 1108 : 567 - 577
  • [32] Attachment anxiety is related to Epstein-Barr virus latency
    Fagundes, Christopher P.
    Jaremka, Lisa M.
    Glaser, Ronald
    Alfano, Catherine M.
    Povoski, Stephen P.
    Lipari, Adele M.
    Agnese, Doreen M.
    Yee, Lisa D.
    Carson, William E., III
    Farrar, William B.
    Malarkey, William B.
    Chen, Mm
    Kiecolt-Glaser, Janice K.
    BRAIN BEHAVIOR AND IMMUNITY, 2014, 41 : 232 - 238
  • [33] Epstein-Barr virus latency: current and future perspectives
    Kempkes, Bettina
    Robertson, Erie S.
    CURRENT OPINION IN VIROLOGY, 2015, 14 : 138 - 144
  • [34] TRANS-ACTIVATORS AND LATENCY OF THE EPSTEIN-BARR VIRUS
    CHEVALLIERGRECO, A
    MANET, E
    CHAVRIER, P
    BUISSON, M
    BIEMONT, MC
    URIER, G
    DAILLIE, J
    SERGEANT, A
    BULLETIN DU CANCER, 1987, 74 (06) : 662 - 663
  • [35] EPSTEIN-BARR VIRUS WITH HETEROGENEOUS DNA DISRUPTS LATENCY
    MILLER, G
    RABSON, M
    HESTON, L
    JOURNAL OF VIROLOGY, 1984, 50 (01) : 174 - 182
  • [36] Epstein-Barr virus infection and gastrointestinal diseases
    Paraskevas, E.
    Dimitroulopoulos, D.
    ANNALS OF GASTROENTEROLOGY, 2005, 18 (04): : 386 - 390
  • [37] Epstein-Barr virus and associated diseases.
    deThe, G
    ANNALES DE MEDECINE INTERNE, 1997, 148 (05): : 357 - 366
  • [38] ANTIBODIES TO EPSTEIN-BARR VIRUS IN NEUROLOGICAL DISEASES
    GOTLIEBSTEMATSKY, T
    ARLAZOROFF, A
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1976, 28 (01) : 115 - 120
  • [39] IMMUNOLOGY OF EPSTEIN-BARR VIRUS IN LYMPHOPROLIFERATIVE DISEASES
    BACHMANN, AE
    GIRAUDOC.LC
    BRAUN, M
    MEDICINA-BUENOS AIRES, 1974, 34 (02) : 157 - 166
  • [40] Vaccine Development for Epstein-Barr Virus
    Cohen, Jeffrey I.
    HUMAN HERPESVIRUSES, 2018, 1045 : 477 - 493